FDA Approval: Adagrasib

Episode
138
Soundcloud
Share

This week, the FDA granted accelerated approval to Adagrasib to treat advanced NSCLC with a KRAS G12C mutation after at least one prior line of systemic therapy.  In this episode of Lung Cancer Considered, host Dr. Stephen Liu and two guests discuss the approval and what impact it will have on patients and clinicians. Joining the podcast are Dr. Joshua Sabari (@JSabari), assistant professor of Medicine and Thoracic Oncologist at NYU Perlmutter Cancer Center in New York City, and Dr. Sheena Bhalla (@SheenaBhallaMD), assistant professor of Medicine and Thoracic Oncologist at UT Southwestern Medical Center in Dallas.

Guest
Stephen Liu, MD
Stephen Liu

MD

Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics
Georgetown Lombardi Comprehensive Cancer Center
Joshua Sabari
Joshua Sabari

MD

Director Inpatient Medical Oncology
NYU Langone Health
Sheena Bhalla
Sheena Bhalla

Md

Assistant Professor in the Department of Internal Medicine
UT Southwestern Medical Center Harold C. Simmons Comprehensive Cancer Center

Other Podcast

Lung Cancer in Brazil
Episode
141
Patient Advocacy Groups Podcast
Episode
140
Radon Podcast
Episode
139
Lung Cancer in Israel (Hebrew)
Episode
139